WWWenyu Wu

Wenyu Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenyu Wu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics

    by Wenyu Wu, Guoqiang Shao, Yilin Xue, Jun Chen, Zhaoyang Zhao, Jingjing Fu, Rui Yang, Hai Qian, Hanmei Xu

    Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.

  • Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68 Ga-PET Radiotracers

    by Yang Zhang, Wenyu Wu, Qiang Ren, Yajing Wang, Li Zhong, Zhipeng Hu, Bo Luo, Shengcong Chen, Shunmin Xu, Feng Wang, et al.

    Triple-negative breast cancer (TNBC) lacks effective molecular targets for imaging. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in the mesenchymal-like (claudin-low) subtype of TNBC. Here, we developed two optimized linear peptide radiotracers, DR1 and DR2, derived from the complementarity-determining regions (CDR) of an anti-ROR1 antibody, conjugated with DOTA and labeled with 68Ga. Both peptides showed nanomolar binding affinities (KD = 93.4 ± 8.2 nM for DR1 and 38.0 ± 4.6 nM for DR2) and favorable target-binding properties. [68Ga]Ga-DOTA-DR2 exhibited excellent in vitro stability (≥95% radiochemical purity after 4 h in human serum), rapid in vivo clearance (t1/2β = 0.66 ± 0.11 h), and specific cellular uptake. Micro-PET/CT imaging in MDA-MB-231 xenograft mice revealed rapid tumor visualization, with a peak tumor uptake of 2.75 ± 0.61 %ID/g at 1 h and a tumor-to-muscle ratio of 7.98 at 2 h. Blocking studies confirmed ROR1-specific targeting. Collectively, [68Ga]Ga-DOTA-DR2 may represent a promising PET tracer for imaging ROR1-positive mesenchymal-like TNBC, providing a foundation for further optimization.


  • Open Access

    Preclinical and First-In-Human Evaluation of 68 Ga-PSMA-33, a Novel PSMA Radiotracer with Low Background Signal

    by Wenyu Wu, Xiaochen Yao, Fei Yu, Jiang Wu, Bo Luo, Liang Shi, Pengjun Zhang, Rui Yang, Yue Huang, Jun Tang, et al.

    Purpose: this study aimed to investigate the potential of a novel 68Ga-labeled PSMA-targeted radiotracer, 68Ga-PSMA-33, as a diagnostic tool for prostate cancer in preclinical and pilot clinical studies. Methods: 68Ga-PSMA-33 was radiolabeled using an iQS-TS automated module, and its radiochemical purity and in vitro stability were analyzed via radio-HPLC. The specificity and binding affinity for PSMA were determined in LNCaP (PSMA+) cells. A head-to-head comparison with 68Ga-PSMA-617 was performed in murine models through biodistribution, pharmacokinetic, and micro-PET/CT imaging studies. The clinical phase involved 68Ga-PSMA-33 PET/CT imaging in seven patients with prostate cancer, two of whom also underwent 68Ga-PSMA-617 imaging for direct comparison. Semiquantitative assessment of physiologic biodistribution and tumor burden was conducted, and the radiation dosimetry of 68Ga-PSMA-33 was estimated. Results: 68Ga-PSMA-33 was efficiently prepared with a labeling yield of 77.5 ± 7.23%, radiochemical purity exceeding 99%, and specific activity of 45.28 ± 6.37 GBq/μmol. The labeled compound demonstrated a high affinity for PSMA (0.103 ± 0.03 nM), along with high hydrophilicity (Log P = −2.84 ± 0.13). Micro-PET/CT imaging revealed rapid clearance and prominent tumor uptake of the tracer, achieving a significantly higher tumor-to-muscle ratio than 68Ga-PSMA-617 (88.85 ± 8.39 vs 30.18 ± 3.39, p < 0.001) at 4 h postinjection. A total of nearly 400 tumor lesions were identified in PET/CT imaging across the 7 patients with prostate cancer. The mean SUVmax values of primary tumors, lymph node metastases, liver metastases, and bone metastases were 22.24 ± 4.77, 10.48 ± 2.16, 21.76 ± 3.82, and 30.25 ± 2.80 at 1 h postinjection, respectively. Clinical 68Ga-PSMA-33 PET/CT studies further confirmed its favorable biodistribution and kinetics, exhibiting a significantly higher tumor-to-muscle ratio than 68Ga-PSMA-617 at 3 h postinjection in both lymph node metastases (23.64 ± 6.68 vs 17.47 ± 7.53, p < 0.01) and bone metastases (83.33 ± 18.80 vs 61.63 ± 13.26, p < 0.001). The radiation dose of 68Ga-PSMA-33 was within an acceptable range, with an effective dose of (7.38 ± 1.44) × 10–3 mSv/MBq. The kidneys were the critical organ, receiving the highest absorbed dose of (7.35 ± 2.64) × 10–2 mGy/MBq. Conclusion: 68Ga-PSMA-33 demonstrated comparable tumor uptake while providing a higher tumor-to-background ratio and lower radiation exposure than 68Ga-PSMA-617, making it a promising novel tracer for prostate cancer diagnosis.